Danaher Is Poised For 'A Good Year In Bioprocessing': Analyst
Danaher Is Poised For 'A Good Year In Bioprocessing': Analyst
Danaher completed a spinoff of its Environmental & Applied Solutions business in 2023. The company then emerged as a "pure-play LS tools company with operating companies in the Biotechnology, Life Sciences, and Diagnostics end-markets," Johnson added.Shares of Danaher Corp (NYSE:DHR) tanked in early trading on Tuesday.
丹納赫公司（紐交所：DHR）的股價在週二早盤交易中大跌。
Stifel analyst Jacob Johnson says the company is poised for a gradual recovery in 2025. It could generate high-single-digit growth in the longer term, he predicts.
Stifel的分析師Jacob Johnson表示，該公司有望在2025年逐漸復甦。他預測，在較長期內可能會實現高個位數的增長。
The Danaher Thesis: Johnson initiated coverage of Danaher with an Overweight rating and price target of $315.
丹納赫投資觀點：Johnson開始對丹納赫進行覆蓋，並給予超重評級，目標股價爲315美元。
Danaher completed a spinoff of its Environmental & Applied Solutions business in 2023. The company then emerged as a "pure-play LS tools company with operating companies in the Biotechnology, Life Sciences, and Diagnostics end-markets," Johnson added.
丹納赫在2023年完成了對其環保及應用解決方案業務的分拆。隨後，該公司成爲一個"以生物技術、生命科學和診斷終端市場爲運營公司的純粹的LS工具公司"，Johnson補充道。
Check out other analyst stock ratings.
查看其他分析師的股票評級。
The EAS spinoff eliminated much of Danaher's industrial exposure. As a life sciences company, it remains focused on "higher growth, recurring revenue, and margins that warrant a higher multiple," the analyst stated.
環保及應用解決方案業務的分拆消除了丹納赫的大部分工業風險。作爲一個生命科學公司，它仍專注於"更高的增長、可重複的營業收入以及值得更高估值的利潤率"，分析師表示。
"Like the broader space, DHR has faced headwinds over the last 12 to 18 months from bioprocessing destocking, the funding environment, China, and the roll-off from COVID," he wrote, while expressing optimism around "a gradual recovery in 2025 (with a good year in bioprocessing)."
"與整個領域一樣，DHR在過去12到18個月裏面臨來自生物加工去庫存、融資環境、中國以及COVID減退的阻力，"他寫道，同時表達了對"2025年逐漸復甦（生物加工領域有良好表現）"的樂觀看法。
DHR Price Action: Danaher shares declined by 1.05% to $275.07 at the time of publication on Tuesday.
在週二的發表時，丹納赫股價下跌1.05%，至275.07美元。
Read More:
閱讀更多：
- Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
- 吉姆·克萊默表示不贊成購買這家醫療保健股票，建議繼續持有康斯泰瑞能源股票：'漲幅巨大'。
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。